Sales grew 40% year-over-year, driven by proprietary X-ray products and international partnerships. Despite higher revenues, losses widened due to increased development costs. Additional financing will be needed in 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.